Stoke Therapeutics, Inc. (NASDAQ:STOK) Major Shareholder Sells $41,760,000.00 in Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) major shareholder Skorpios Trust sold 3,600,000 shares of the business’s stock in a transaction that occurred on Wednesday, April 17th. The stock was sold at an average price of $11.60, for a total value of $41,760,000.00. Following the completion of the transaction, the insider now directly owns 10,843,681 shares in the company, valued at $125,786,699.60. The sale was disclosed in a legal filing with the SEC, which is available through this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Stoke Therapeutics Trading Down 0.6 %

Shares of Stoke Therapeutics stock opened at $11.65 on Friday. The company has a 50 day moving average of $8.62 and a 200-day moving average of $5.93. The company has a market cap of $539.40 million, a PE ratio of -4.92 and a beta of 0.77. Stoke Therapeutics, Inc. has a 1-year low of $3.35 and a 1-year high of $16.40.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings results on Monday, March 25th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.62) by $0.02. The business had revenue of $2.80 million during the quarter, compared to analyst estimates of $3.70 million. Research analysts forecast that Stoke Therapeutics, Inc. will post -2.28 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on STOK shares. TD Cowen raised shares of Stoke Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Tuesday, March 26th. Cantor Fitzgerald reissued an “overweight” rating on shares of Stoke Therapeutics in a report on Thursday, April 4th. HC Wainwright reaffirmed a “buy” rating and set a $35.00 price target on shares of Stoke Therapeutics in a report on Tuesday, March 26th. Needham & Company LLC reiterated a “buy” rating and issued a $22.00 price objective on shares of Stoke Therapeutics in a report on Thursday, April 11th. Finally, Canaccord Genuity Group lifted their target price on shares of Stoke Therapeutics from $18.00 to $21.00 and gave the stock a “buy” rating in a report on Tuesday, March 26th. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, Stoke Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $19.63.

Hedge Funds Weigh In On Stoke Therapeutics

A number of institutional investors have recently made changes to their positions in STOK. Ensign Peak Advisors Inc bought a new stake in Stoke Therapeutics in the 1st quarter worth approximately $25,000. Point72 Hong Kong Ltd purchased a new stake in Stoke Therapeutics during the first quarter valued at about $27,000. Great West Life Assurance Co. Can lifted its stake in shares of Stoke Therapeutics by 46.7% in the 1st quarter. Great West Life Assurance Co. Can now owns 3,387 shares of the company’s stock valued at $28,000 after acquiring an additional 1,078 shares during the last quarter. UBS Group AG purchased a new stake in Stoke Therapeutics during the 3rd quarter valued at about $47,000. Finally, Quantbot Technologies LP grew its position in Stoke Therapeutics by 207.1% during the 1st quarter. Quantbot Technologies LP now owns 4,300 shares of the company’s stock worth $90,000 after acquiring an additional 2,900 shares during the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.